Laboratory Of America
As on 21 Apr, 2026 | 01:29 IST
| Open | 269.80 |
| Previous Close | 270.68 |
| Beta | 0.32 |
| High | 271.26 |
| Low | 265.80 |
| TTM EPS See historical trend | 16.44(+12.83% YoY) |
| 52 Week High | 293.50 |
| 52 Week Low | 209.45 |
| TTM PE See historical trend | 16.38(High PE) |
| Mkt. Cap ($ Billion) | 22.64 |
| Dividend Yield | 1.15 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 268.42 |
| 10 | 268.49 |
| 20 | 268.28 |
| 50 | 273.37 |
| 100 | 267.88 |
| 200 | 268.17 |
Returns
| 1 Week | 1.88% | |
| 1 Month | 2.37% | |
| 3 Months | -0.80% | |
| YTD | 7.32% | |
| 1 Year | 23.94% | |
| 3 Years | 16.28% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| UnitedHealth | 323.45 | -0.36 | 298.30 | 19.84 | 16.31 | 2.64 | 453.03/234.61 | 16.41 | Very Bearish |
| Thermo Fisher Scientific | 526.02 | -0.11 | 200.70 | 23.01 | 22.87 | 0.30 | 643.99/385.72 | 10.89 | Very Bullish |
| Danaher | 195.78 | 0.53 | 141.21 | 25.07 | 7.80 | 0.56 | 242.75/180.09 | 3.17 | Neutral |
| HCA | 478.17 | -2.01 | 126.43 | 16.92 | 28.26 | 0.62 | 556.52/314.43 | -3.18 | Very Bullish |
| McKesson | 859.04 | -0.85 | 112.88 | 22.86 | 37.58 | 0.37 | 998.98/637.00 | -3.03 | Very Bullish |
Market news
- Wall St ends mixed, notches weekly gains as investors parse Middle East negotiationsApril 11, 2026 8:53 AM
- Wall Street skids as Middle East turmoil fans inflation fearMarch 21, 2026 9:02 AM
- Wall Street closes lower, posts weekly loss as war on Iran fuels inflation worriesMarch 14, 2026 8:59 AM
- US stocks close down as oil spikes 12%, job market weakensMarch 7, 2026 9:27 AM
About the company
Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The Company serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers.